Found 15 bookmarks
Custom sorting
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
“Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY.”
Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY.
#vaccine#Novavax
·sciencedirect.com·
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
New RCT study shows the "conventional" Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options.
New RCT study shows the "conventional" Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options.

“New RCT study shows the ‘conventional’ Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options. Side effects are a leading cause of COVID vaccine hesitancy. This can help.”

#Novavax#vaccine#analysis#Discussion
·x.com·
New RCT study shows the "conventional" Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options.
A trio of Novavax preprints, showing 1) remarkable durability 6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.
A trio of Novavax preprints, showing 1) remarkable durability 6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.
“A trio of Novavax preprints, showing 1) remarkable durability >6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.”
#Novavax#vaccine#analysis#Discussion#compilations
·x.com·
A trio of Novavax preprints, showing 1) remarkable durability 6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-70 years old.
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-70 years old.
From a randomized trial, proof that the Novavax booster induces less acute side effects and more sustained levels of anti-spike IgG antibodies than mRNA shots
#Novavax#vaccine#Immune system#antibodies
·journalofinfection.com·
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-70 years old.
Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.
Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.
“Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.”
#Novavax#vaccine
·x.com·
Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.
2024-Q2-Earnings-Presentation.pdf
2024-Q2-Earnings-Presentation.pdf

August, 2024

Excellent broad cross neutralization to variants with the upcoming JN.1 Novavax COVID vaccine, including some of the best responses to variants that are likely to be dominant this late fall and early winter

#Novavax#vaccine
·novavax.widen.net·
2024-Q2-Earnings-Presentation.pdf
Flew in from Asia today to learn the exciting news that Novavax's JN.1 booster has been approved!
Flew in from Asia today to learn the exciting news that Novavax's JN.1 booster has been approved!

excellent explanation thread of differences between Novavax and MRNA vaccines.

“Novavax, likely because its stimulation method is slow and steady, instead of creating a hot and heavy pseudoinfection in your muscles like RNA, does not induce the IgG4 isotype switch. It instead generates more IgG3, with the most Fc effector function.”

#Novavax#vaccine
·x.com·
Flew in from Asia today to learn the exciting news that Novavax's JN.1 booster has been approved!